Clinical Trials Directory

Trials / Completed

CompletedNCT05385536

Evaluating UTI Outcomes in at Risk Populations

Status
Completed
Phase
Study type
Observational
Enrollment
7,921 (actual)
Sponsor
Pathnostics · Industry
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

This is a multicenter, observational comparative cohort, study to evaluate the UTI related adverse event rates between Guidance® UTI clinical pathway versus the current traditional clinical pathways for urine testing.

Detailed description

Clinical sites will be identified by an internal database, prepared by the sponsor, based on previous experience with the sites. Study allocation will based on their current usage of Guidance® UTI and the reporting pathway (described above) will be implemented. Those who currently routinely use Guidance® UTI testing procedures will be over sampled 2:1 over those who do not routinely use Guidance® UTI. Larger clinical care systems with multiple care sites may have locations allocated to different cohort. The basis for cohort allocation will be based on the availability and willingness of providers in these markets to implement infrastructure for collecting and reporting of Guidance® UTI clinical pathway. The comparative cluster cohort will be selected from select geographies within the U.S. based on size of general population served matching to those enrolled in the Guidance® UTI clinical pathway. The method of patient care and management (e.g., test ordering and antimicrobial initiation) is at the discretion of the treating physicians. Specimens collected for suspected UTI may be sent to Pathnostics for standard bacterial identification and sensitivities. Guidance® UTI can only be performed at Pathnostics, whereas urine cultures may be performed at any lab. Trained and experienced clinical lab scientists at Pathnostics are always available to assist the ordering provider with results interpretation or any other questions on the report they may have.

Conditions

Timeline

Start date
2022-07-18
Primary completion
2024-03-29
Completion
2024-03-29
First posted
2022-05-23
Last updated
2024-05-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05385536. Inclusion in this directory is not an endorsement.